登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事、高级管理人员保证信息披露的内容真实、准确、完整、及时，没有虚假记载、误导 性陈述或重大遗漏。 经上海证券交易所审核同意，德力佳传动科技（江苏）股份有限公司（以下简称"德力佳"、"发行 人"或"公司"）人民币普通股股票将于2025年11月7日在上海证券交易所主板上市，上市公告书全文和首 次公开发行股票的招股说明书全文披露于上海证券交易所网站（http://www.sse.com.cn/）和符合中国证 监会规定条件网站（中国证券网：https://www.cnstock.com；中证网：https://www.cs.com.cn；证券时报 网：https://www.stcn.com；证券日报网：http://www.zqrb.cn；经济参考网：http://www.jjckb.cn；中国金 融新闻网：https://www.financialnews.com.cn；中国日报网：https://www.chinadaily.com.cn）披露，供投 资者查阅。 一、上市概况 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初期的投 ...

Group 1: Company Overview - Dapeng Industrial is a leading manufacturer of specialized intelligent equipment for industrial precision cleaning, primarily serving the automotive and new energy sectors [2][3] - The company is actively expanding into machine vision detection products to address identified gaps in the market, leveraging its existing technology and market resources [3] - Dapeng Industrial has established long-term partnerships with major automotive manufacturers, including BYD, Changan, and Geely, among others [3] Group 2: Financial Performance - Dapeng Industrial's accounts receivable from 2022 to mid-2025 were reported as 89.63 million, 83.68 million, 130.99 million, and 109.95 million respectively, indicating a significant amount of receivables relative to sales [4] - The company warns that economic downturns or adverse changes in client creditworthiness could extend the collection period for accounts receivable, impacting cash flow and operations [4] Group 3: Market Position and Products - Fengbei Bio, established in 2014, focuses on the comprehensive utilization of waste oil resources, with a secondary business in oil chemical products [5] - The company has achieved a market share of approximately 4.68% in the biodiesel sector, ranking sixth in production capacity in China [6] - Fengbei Bio's revenue from waste oil resource utilization consistently accounts for over 75% of its total income, highlighting its core business focus [7] Group 4: Innovation and Patents - Fengbei Bio has secured 135 patents, including 33 domestic invention patents and 3 international invention patents, showcasing its commitment to innovation [5] - The company has established research centers to enhance its technological capabilities in oil processing and utilization [5] Group 5: Risks and Challenges - Fengbei Bio faces potential supply constraints if it fails to establish timely partnerships with waste oil recovery enterprises, which could adversely affect its operations [7] - The company also cautions that significant increases in waste oil procurement prices could impact its profitability if product prices cannot be adjusted accordingly [7]

Listing Overview - Suzhou Fengbei Biotechnology Co., Ltd. will be listed on the Shanghai Stock Exchange on November 5, 2025, with a total share capital of 143.5 million shares, of which 35.9 million shares are newly issued [1][4]. Initial Public Offering (IPO) Details - The IPO price is set at 24.49 CNY per share, corresponding to a price-to-earnings (P/E) ratio of 21.28 times based on the 2024 earnings before non-recurring gains and losses [4]. - The total number of shares available for public trading after the IPO will be 31.05 million shares, accounting for 21.64% of the total share capital [3][4]. Market Comparisons - The average static P/E ratio for the waste resource comprehensive utilization industry is reported at 64.73 times as of October 22, 2025 [5]. - The diluted P/E ratio of the company at the IPO price is 30.47 times, which is lower than the industry average and comparable companies' average P/E ratios [6]. Trading Risks - The first five trading days will have no price fluctuation limits, which may lead to significant price volatility [2]. - The limited number of circulating shares may pose liquidity risks in the initial trading period [3]. Contact Information - The company is located at Jiangsu Yangtze River International Chemical Industrial Park, and the contact number is 0512-58329931 [8]. - The lead underwriter is Guotai Junan Securities Co., Ltd., located in Shanghai, with a contact number of 021-38032666 [9].

Group 1: Navan (NAVN) - Navan went public on October 30, raising approximately $923 million by issuing 36.92 million shares at an initial price of $25 per share [3] - On its first trading day, Navan's stock opened at $22, a 12% decline from the offering price, and closed at $20, marking a 20% drop, with a total market capitalization of $4.965 billion [1][3] - As of July 31, 2025, Navan reported revenue of $329 million and a net loss of $99.88 million, with over 10,000 active customers [3] Group 2: Dynamix Corporation III (DNMXU) - Dynamix Corporation III, a SPAC, also went public on the same day, raising $175 million by issuing 17.5 million units at an initial price of $10 per unit [4] - The stock had a trading range with a high of $10.15 and a low of $10.12 on its first day, with a total market capitalization of $177 million [5] - The company targets sectors such as energy, power, and digital infrastructure, focusing on greenhouse gas emissions technologies and critical infrastructure services for data centers [5]

Core Viewpoint - The A-share market witnessed the listing of four new stocks on October 28, marking the highest number of new listings in a single day for the year [1] Group 1 - Four new stocks were launched in the A-share market on October 28 [1] - This event set a new record for the number of listings in a single day in 2023 [1]

New IPOs and Listings - Two new stocks are available for subscription: Delijia (603092.SH) on the Shanghai Stock Exchange and Zhongcheng Consulting (920003.BJ) on the Beijing Stock Exchange [1] - Four stocks are listed today: Bibete (688759.SH), Xi'an Yicai (688783.SH), Heyuan Bio (688765.SH), and Taikaiying (920020.BJ) [1] Delijia (603092.SH) - Delijia specializes in the R&D, production, and sales of high-speed heavy-load precision gear transmission products, primarily for wind power generation [2][7] - The IPO price is 46.68 CNY per share, with an institutional offering price of 47.68 CNY, and a market capitalization of 16.8 billion CNY [5] - The company has a projected market share of 10.36% globally and 16.22% in China for wind power transmission equipment by 2024, ranking third globally and second in China [7] - Delijia's revenue from onshore wind power is expected to be 36.25 billion CNY in 2024, accounting for 98.57% of its total revenue [7] Zhongcheng Consulting (920003.BJ) - Zhongcheng Consulting focuses on engineering consulting services and has ranked among the top five in Jiangsu Province for engineering cost consulting revenue from 2021 to 2024 [8][11] - The IPO price is 14.27 CNY per share, with a market capitalization of 1.4 billion CNY [11] - The company plans to invest 1.23 billion CNY in building an engineering consulting service network and 0.77 billion CNY in R&D and information technology [11] Taikaiying (920020.BJ) - Taikaiying is the first company in the mining and construction tire segment to be listed on the Beijing Stock Exchange, recognized as the "first tire stock" on the exchange [15][19] - The IPO price is 7.50 CNY per share, with a market capitalization of 750 million CNY [18] - The company holds the number one market share in the domestic market for large-tonnage crane tires [19] Xi'an Yicai (688783.SH) - Xi'an Yicai is a leading manufacturer of 12-inch silicon wafers, ranking first in China and sixth globally in terms of production capacity [21][22] - The IPO price is 8.62 CNY per share, with a market capitalization of 34.81 billion CNY [21] - The company has a projected capacity of 120,000 wafers per month by 2026, which will meet 40% of the demand in mainland China [22] Heyuan Bio (688765.SH) - Heyuan Bio focuses on the research and development of plant-derived recombinant protein expression technology and has developed several pharmaceutical products [33][38] - The IPO price is 29.06 CNY per share, with a market capitalization of 10.39 billion CNY [35] - The company plans to invest 19.09 billion CNY in the construction of a plant for recombinant human serum albumin and 7.94 billion CNY in new drug development [37]

Group 1: Company Overview - Danah Biotechnology, established on March 10, 2014, focuses on early diagnosis of invasive fungal diseases and other pathogenic microorganisms, recognized as a national high-tech enterprise and a key specialized "little giant" enterprise supported by the state [2] - The main products include diagnostic reagents and instruments, with reagents accounting for 90.52% of revenue in 2024, while instruments contribute 6.06% [2] - Danah holds a market share of approximately 30% in China's invasive fungal disease diagnostic reagent market as of 2022 [2] Group 2: Product and Supply Chain - The core raw material for Danah's main product, the (1-3)-β-D-glucan test kit, is horseshoe crab blood, which accounted for 21.34% to 32.57% of revenue from 2022 to June 2025 [3] - Horseshoe crabs are classified as a national second-level protected animal, leading to stricter regulations on their utilization, creating uncertainty regarding future supply [3] - Danah has sufficient inventory of horseshoe crab blood to meet production needs for over five years and has begun exploring overseas procurement channels [3] Group 3: Market Position and Financial Performance - Marco Polo, a leading manufacturer and seller of building ceramics, has production bases in multiple locations, with revenues of 8.661 billion, 8.925 billion, and 7.324 billion from 2022 to 2024 [4] - The company ranks first in the domestic building ceramics industry in terms of revenue from 2022 to 2024, indicating strong market presence [4] - Marco Polo's sales model includes both distribution and direct sales, with a significant portion of revenue coming from glazed tiles, which have seen an increasing trend in sales [4][6] Group 4: Revenue Trends and Risks - Marco Polo's main business revenue is projected to decline by 17.95% in 2024 compared to 2023, attributed to changing consumer preferences towards glazed tiles [6] - The company faces potential risks related to fluctuations in the real estate market, which is closely tied to its industry, as indicated by a declining real estate development prosperity index from 2022 to 2024 [6] - Marco Polo also highlights risks associated with raw material and energy price volatility, which could significantly impact profitability if costs cannot be passed on to customers [7]

Company Overview - Marco Polo is a leading company in the domestic building ceramics industry, primarily engaged in the research, production, and sales of building ceramics [1][2] - The company has two major brands: "Marco Polo Tiles" and "Vimel L&D Ceramics," with the "Marco Polo" trademark recognized as a famous Chinese trademark [1][2] - Marco Polo has maintained the highest revenue in the domestic building ceramics industry for three consecutive years, confirming its leading position [1][2] Industry Context - The ceramics industry is experiencing a decline due to the real estate cycle, with national ceramic tile production expected to decrease from 67.30 billion square meters in 2023 to 59.1 billion square meters in 2024, a drop of 12.18% [2] - Despite the shrinking new housing market, there is a structural shift in the building ceramics industry, with increasing demand for home renovations and cross-industry applications [2] - The market share is increasingly concentrating among leading enterprises due to advantages in scale, technology, and brand recognition [2] Financial Performance - For the fiscal year 2024, Marco Polo is projected to achieve revenue of 7.324 billion yuan, a decrease of 17.93% year-on-year, and a net profit of 1.327 billion yuan, down 1.92% year-on-year [3] - The company anticipates a revenue range of 4.850 billion to 5.100 billion yuan for the first nine months of 2025, representing a year-on-year decrease of 7.25% to 11.79% [3] - The net profit for the same period is expected to be between 1 billion and 1.050 billion yuan, reflecting a year-on-year decline of 7.66% to 12.06% [3] IPO and Market Expectations - Marco Polo's IPO involves issuing 11.949 million shares, raising 1.643 billion yuan, with funds allocated to five projects aimed at enhancing production capabilities [3][4] - The company's dynamic price-to-earnings ratio is 12.93, significantly lower than the average of comparable companies at 25.8, indicating a valuation advantage [5] - The IPO price is set at 13.75 yuan per share, which is considered relatively low within the main board context, where new stocks have averaged a 300% increase on their first trading day [5] Market Performance Predictions - Based on recent trends, Marco Polo's first-day performance could see an increase in the range of 220.7% to 234.4%, aligning with the average performance of newly listed stocks [4][5] - Despite the positive brand recognition and valuation advantages, the high fundraising amount and the impact of the real estate cycle may limit the stock's performance on its debut [5]

Listing Overview - The company, DaoShengTianHe Materials Technology (Shanghai) Co., Ltd., is set to list its ordinary shares on the Shanghai Stock Exchange on October 17, 2025 [1][2] - The total share capital after the IPO will be 659,400,000 shares, with 131,880,000 shares being newly issued [4][5] Investment Risks - The initial trading period for the company's shares will have no price fluctuation limits for the first five trading days, which may lead to significant price volatility [3] - The number of freely tradable shares is limited, with only 107,183,716 shares available for trading, representing 16.25% of the total share capital, posing liquidity risks [4] - The IPO price is set at 5.98 CNY per share, resulting in a price-to-earnings (P/E) ratio of 20.37 times based on pre-non-recurring profit for 2024, and 23.24 times based on post-non-recurring profit [5][6] - The company's P/E ratio of 29.05 times based on diluted earnings is higher than the industry average of 27.90 times, indicating potential valuation concerns [6] Financing and Margin Trading - The company's shares will be eligible for margin trading from the first day of listing, which may introduce additional price volatility and market risks [7]

Company Overview - The company, Daoshengtianhe, is a leading supplier in the global wind turbine blade material sector, with its epoxy resin and structural adhesive for wind blades holding the first and third largest market shares globally in 2024 respectively [2] - The company has achieved full coverage of mainstream wind turbine blade types with its epoxy resin products, effectively replacing imports and expanding into new application areas such as photovoltaics, consumer electronics, and semiconductors [2] - In the new energy vehicle and industrial adhesive sectors, the company has received certifications from major clients like BYD and FAW-Volkswagen, and is actively pursuing certifications from Tesla and CATL [2] Financial Performance - The company reported revenues of 3.436 billion yuan, 3.202 billion yuan, and 3.238 billion yuan for the years 2022, 2023, and 2024 respectively, with year-on-year growth rates of 9.89%, -6.81%, and 1.13% [3] - The net profit attributable to shareholders for the same years was 110 million yuan, 155 million yuan, and 155 million yuan, with growth rates of 30.08%, 40.12%, and 0.01% [3] - For the first three quarters of 2025, the company achieved a revenue of 2.698 billion yuan, a year-on-year increase of 26.92%, and a net profit of 153 million yuan, up 56.89% from the previous year [3] IPO Details - The company’s IPO involves an initial issuance of 13.188 million shares, raising approximately 789 million yuan [4] - The raised funds will be allocated to a project for producing high-end adhesives and composite resin systems, with a total investment of 571 million yuan, and 135 million yuan will be used to repay bank loans [4] Market Outlook - The wind power industry in China is expected to see a record high of 79.82 GW in new installed capacity in 2024, with a forecasted doubling of new installations in the first half of 2025 compared to the same period in 2024 [3] - The global market for wind blade epoxy resin is projected to maintain a long-term growth trend, with compound annual growth rates of 6.56% globally and 6.45% in China from 2024 to 2030 [3] Valuation and Pricing - The company has a dynamic price-to-earnings ratio of 20.88, significantly lower than the average of 66.16 for comparable companies [5] - The IPO price is set at 5.98 yuan per share, which is among the lowest for main board IPOs this year, with only two other new stocks priced lower [6] - If the company achieves the average first-day performance of recent IPOs, the expected price increase could range from 206.3% to 222.4% [5][6]